ID   TOV-3392D
AC   CVCL_A1SS
SY   TOV3392D
DR   cancercelllines; CVCL_A1SS
DR   Wikidata; Q105511248
RX   PubMed=32784519;
CC   Doubling time: 2.1 +- 0.4 days (PubMed=32784519).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Unspecified (PubMed=32784519).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Miscellaneous: STR profile from personal communication of Mes-Masson, Anne-Marie.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12,14
ST   D16S539: 9,11
ST   D21S11: 28,30
ST   D5S818: 11,13
ST   D7S820: 9,11
ST   TH01: 9,9.3
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C40078; Ovarian clear cell adenocarcinoma
DI   ORDO; Orphanet_398971; Clear cell adenocarcinoma of the ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   42Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 19-12-24; Version: 7
//
RX   PubMed=32784519; DOI=10.3390/cancers12082222; PMCID=PMC7465288;
RA   Sauriol A., Simeone K., Portelance L., Meunier L.,
RA   Leclerc-Desaulniers K., de Ladurantaye M., Chergui M.,
RA   Kendall-Dupont J., Rahimi K., Carmona E., Provencher D.M.,
RA   Mes-Masson A.-M.;
RT   "Modeling the diversity of epithelial ovarian cancer through ten novel
RT   well characterized cell lines covering multiple subtypes of the
RT   disease.";
RL   Cancers (Basel) 12:2222.1-2222.26(2020).
//